Medtronic Activa Postmarket Study On Parkinson’s Will Begin By Summer
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's 230-patient, three-year post-approval study of its Activa Parkinson's disease neurostimulation therapy will begin enrollment by this summer
You may also be interested in...
“Substantial” Device Effectiveness Proposed As Coverage Decision Category
CMS will allow the Medicare Coverage Advisory Committee to designate a new effectiveness category for devices showing a "substantial clinical benefit" over existing technologies, Acting Chief Clinical Officer Sean Tunis indicated Sept. 25
“Substantial” Device Effectiveness Proposed As Coverage Decision Category
CMS will allow the Medicare Coverage Advisory Committee to designate a new effectiveness category for devices showing a "substantial clinical benefit" over existing technologies, Acting Chief Clinical Officer Sean Tunis indicated Sept. 25
Medtronic Activa Medicare Coverage Decision Favored By Tech Assessment
Clinical studies evaluating bilateral deep-brain stimulation (DBS) for treatment of Parkinson's disease support improved health outcomes associated with the procedure, a BlueCross BlueShield Association technology assessment suggests